NCT03687125 - Tinostamustine Conditioning and Autologous Stem Cell | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

April 17, 2019

Study Completion Date

April 17, 2019

Conditions

Multiple Myeloma in RelapseMultiple Myeloma ProgressionMultiple Myeloma With Failed Remission

Interventions

DRUG

Tinostamustine

Participants received tinostamustine IV injection.

PROCEDURE

Autologous Stem Cell Transplant (ASCT)

Undergo autologous stem cell transplant

Trial Locations (12)

Memorial Sloan Kettering Cancer Centre, New York

Carolinas Healthcare System, Charlotte

University of Alabama, Birmingham

Vanderbilt-Ingram Cancer Center, Nashville

Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital, Milwaukee

University of Kansas Medical Center Kansas City, Kansas City

University of Texas MD Anderson Cancer Center, Houston

Oslo Myeloma Center, Oslo University Hospital, Oslo

Universitatsspital Basel, Basel

Universitatsspital Bern, Bern

Department of Clinical Research Oncology/Hematology, Kantonsspital St. Gallen, Sankt Gallen

University Hospital Zurich, Zurich